Parkinson Disease

>

Latest News

FDA Accepts Protocol for Annovis Bio’s Buntanetap Phase 3 Alzheimer Disease Trial
FDA Accepts Protocol for Annovis Bio’s Buntanetap Phase 3 Alzheimer Disease Trial

January 9th 2025

Buntanetap is an oral molecule designed to inhibit the production of multiple neurotoxic proteins and is under investigation for treatment of Alzheimer Disease, Parkinson’s Disease, and other neurodegenerative diseases.

Air Pollution Linked to Parkinson Disease with Regional Differences, Hot Spots Identified
Air Pollution Linked to Parkinson Disease with Regional Differences, Hot Spots Identified

February 27th 2023

Beer Brews Up Good Medicine for the Brain
Beer Brews Up Good Medicine for the Brain

February 3rd 2015

Foreign-Body Retrieval: Diamonds in the Rugae
Foreign-Body Retrieval: Diamonds in the Rugae

May 29th 2013

© 2025 MJH Life Sciences

All rights reserved.